Ten horses (Equus caballus) were vaccinated with strain TC-83 Venezuelan equine encephalomyelitis (VEE) virus vaccine. Febrile responses and leukopenia due to a reduction of lymphocytes and neutrophils were observed in all animals. Viremias were demonstrable in eight horses, with a maximum of 10 5 median tissue culture infectious dose units per ml of serum in two horses. Clinical illness with depression and anorexia were observed in five horses. Neutralizing (N), hemagglutinationinhibiting, and complement-fixing antibodies to the vaccine virus were demonstrable by 5, 6.5, and 7 days, respectively, after vaccination. Differential titrations of serum to six VEE strains revealed high titers of N antibody to vaccine virus, moderate titers to the epizootic Trinidad donkey no.
During the past 3 years, major epizootics of Venezuelan equine encephalomyelitis (VEE) have occurred among horses in Central America (7, 15, 17 (1) . Although initial evaluation of the vaccine was done in burros (9) prior to its use in Central America, no information was available regarding clinical effects in horses, the occurrence of viremia, the quality and quantity of antibodies produced by the vaccinated horses, and most critically, the duration of immunity against equine virulent strains of VEE virus.
The present study was undertaken to answer these and other questions.
MATERIALS AND NIETHODS Horses. Ten crossbred Panamanian geldings (Equus caballus) from 3 to 10 years of age were vaccinated. Criteria for selection were lack of neutralizing (N) antibody to VEE virus and good health. All were housed in an insect-proof isolation unit in Gualaca, Chiriqui Province, Panama, for the duration of the acute-phase vaccination and challenge studies.
Vaccine. Strain TC-83 attenuated VEE vaccine was used in all the studies. The vaccine virus was derived from Trinidad donkey no. 1 strain of VEE and was passed serially 83 times in fetal guinea pig heart cell cultures (1, 14) . The 100-dose vials of vaccine were each reconstituted with 50 ml of Hanks Clinical examinations and specimens. Samples were taken from all horses before vaccination for base-line data. Rectal temperatures, pulse and respiration rates, and serum samples were obtained twice daily from the initial eight animals. Oxalated blood samples also were taken daily for 9 days for hemoglobin, hematocrit, and leukocyte determinations. Urine was collected daily from most animals; specific gravity determinations were made with a hydrometer, and other tests with Hema-Combistix (Ames Co., Elkhart, Ind.). Swab specimens were taken twice daily from the eyes, nose, mouth, and feces of each horse and suspended in veal infusion broth containing 500 units of penicillin and 500 jg of dihydrostreptomycin per ml. The swab specimens and samples of urine and serum were all preserved as described previously (18) . Urine and swab specimens were not taken from horses 9 and 10.
We obtained serum samples at 1, 2, 4, 6, 12, and 14 months after vaccination from the first group of horses, at 1 and 5 months from horse 9, and at 1 and 2 months from horse 10.
Viral isolations. In our experience, comparative titrations of the vaccine virus in suckling mice and Vero cell cultures have yielded no significant differences in sensitivity of the two systems. In the field, titrations were accomplished more easily in suckling mice than in cell cultures which were used in the laboratory. Four culture tubes of a continuous line of African green monkey kidney (Vero) cells were inoculated with 0.1 ml of each specimen. Swab and urine samples were first centrifuged for 15 min at 770 X g to remove debris.
Positive samples were titrated for virus in Vero cell cultures by using a previously unthawed vial of serum and were prepared in serial 10-fold dilutions. Endpoints were determined by the method of Spearman and Karber (6) . Isolates were identified as VEE using the hemagglutination-inhibition (HI) test (3) modified for Microtiter plates (13 Selected sera were titrated differentially against several VEE virus subtypes ( Table 2 ). All of the eight horses tested had N antibody to the vaccine virus and the three epizootic strains 1 month after vaccination. Antibody titers were highest to the vaccine strain, but were still present in all animals to all four of these virus strains 1 year later. In contrast, antibody levels and, particularly, numbers of responders were lower when tested with the enzootic subtypes I-D and I-E; horse 2. When challenged 14 months after vaccination with subtype I-B, antibody increases were demonstrable in the six horses to most of the seven test viruses. Antibody titers to strain TC-83 and subtype I-A, from which TC-83 was derived, did not attain the levels recorded after vaccination. Threefold and twofold increases occurred with subtypes I-B and I-E, respectively, above the levels recorded for the initial response 1 month after vaccination; the responses to subtypes I-C and I-D were only slightly greater than the initial values. At 1 month post-challenge, horses 5 and 6 failed to exhibit N antibody to subtype I-D.
DISCUSSION
There seems little doubt that the TC-83 vaccine for VEE is immunogenic and protective. The development of specific antiviral VEE antibodies after vaccination has been documented in field studies conducted in Panama, Costa Rica (5), and Nicaragua (17) , as well as in experimental studies performed in the U.S. (10, 14) . In the present study, N antibody to the vaccine virus was detectable in all animals within 8 days, reaching titers of at least 1:512 after 1 month. Antibody development to an equine virulent strain (MF-8) occurred less rapidly and to lower levels, and similar antibody patterns also were demonstrable in all animals to the other epizootic viruses. When tested against the enzootic, equine avirulent strains (Walton, unpublished data), very low levels of antibody were detected in some animals. Similar differences in N antibody titers to homologous and heterologus VEE viruses have been described previously in field studies (5, 17; D. H. Martin, Amer. J. Epidemiol., in press). After 1 year, N antibody to the vaccine virus, and the epizootic viruses tested, was still readily detectable in all animals. By contrast, development of CF and HI antibodies to the vaccine virus more closely followed the production of N antibody to epizootic I-B virus. After 4 months, CF antibody was barely detectable in two horses; low levels of HI antibody were demonstrable in three animals after 6 months. As in previously described studies (10, 14) , challenge of two horses shortly after vaccination (2 and 5 months) was resisted. In the face of challenge by equinevirulent virus 14 months after vaccination, horses with minimally detectable levels of antibody to the challenge virus were likewise completely immune. A marked increase in N antibody to the challenge virus subtype I-B, and to a lesser degree to subtype I-E, occurred after challenge. However, these titers did not attain the levels seen in horses recovered from a primary infection with subtype I-B (Walton, unpublished data). More vaccinated animals must be studied over longer periods of time to determine whether there is, in fact, a positive correlation between presence of N antibodies to a given VEE subtype and resistance to challenge, and whether a single vaccination will protect a horse for life.
There was a significant variation in vaccine virus titer among different vials of this vaccine. The vial of vaccine used for inoculation of horse 9 was markedly acid after reconstitution of the product with diluent of a satisfactory initial pH. Suckling mouse titrations indicated <1,000
SMICLD5o units/0.5 ml of vaccine; the response of the horse was mild with low fever, minimal leukocytic changes, and no viremia, but development of N antibody was stimulated. In field studies with this vaccine in Nicaragua (17) and Panama (5), considerable variation in incidence and magnitude of N antibody responses was observed. One of us (T. W.) observed significant colorimetric variation in bottles of Hanks diluent prepared and used in Nicaragua. Diluent varied in color from alkaline (red-violet) to acid (yelloworange); the TC-83 strain has been reported to be highly acid-sensitive (R. W. McKinney, personal communication), and the viable virus in a 100-dose vial with acid pH might soon be inactivated. Another possible explanation for differences in the vaccine response may be related to the vaccine virus itself. The attenuated virus stocks used in these studies were all produced at the same time. Lot 4 vaccine was dispensed and lyophilized on 17 October 1966. By contrast, the lot 5 vaccine was initially frozen at -70 F (ca. -21 C) for 4 years and not lyophilized in multidose vials until 1970. It is reasonable to suggest that some changes could have occurred in the virus during the intervening storage period and after different methods of handling and lyophilization were used. The variations in response may also reflect different routes of inoculation although results in our first group of eight horses inoculated intramuscularly closely paralleled those reported by Henderson et al. (10) using the same vaccine lot and the subcutaneous route.
Mild, clinical illness with fever in TC-83-vaccinated horses has been reported previously (10 (2) .
